3Bolen S, Feldman L, Vassy J, et al. Systematic review : comparative effectiveness and safety of oral medications for type 2 diabetes mel- litus [ J ]. Ann Intern Med,2007,147 (6) :386-399.
4Genuth S. The UKPDS and its global impact [J]. Diabet Med, 2008,25 Suppl 2:57-62.
5Drab SR. Clinical studies of liraglutide ,a novel,once-daily human glu- cagon-like peptide-I analog for improved management of type 2 diabe- tes mellitus[ J]. Pharrnaeotherapy ,2009,29( 12 Pt 2) :43S-54S.
6Vilsb~ll T. The effects of glueagon-like peptide-1 on the beta cell [J]. Diabetes Obes Metab ,2009,11 Suppl 3 : 1 l-18.
7Iizuka K, Tomita R, Suwa T, et al. Normalization of fasting hyper- glycemia is beneficial for successful introduction of small amount of the GLP-1 analog liraglutide in an obese patient with type 2 diabe- tes mellitus [ J ]. Diabetol Int,2012,3 ( 1 ) :61-64.
8Raun K, yon Voss P, Gotfredsen CF, et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed Rats, whereas a dipeptidyl peptidase-IVinhibitor, vildagliptin, does not [ J ]. Diabetes,2007,56 ( 1 ) : 8-15.
9Inoue K, Maeda N, Kashine S, et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference : a pilot study of obese Japanese patients with type 2 diabetes [ J ]. Cardiovascu Diabeto1,2011,10 : 109.
10Sowers JR. Endocrine functions of adipose tissue:focus on adipone- ctin [ J ]. Clin Cornerstone, 2008,9 ( 1 ) : 32 -38.
